Clinical Trial Update: Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating KTE-C19 in combination with atezolizumab in adults with refractory diffuse large B-cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• KTE-C19 (tisagenlecleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Refractory Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-06-26